AU Health partners with Inflo Health to elevate the radiology follow-up process to optimize the patient experience

CONTACT: Lisa Kaylor, AU Health, 706-755-3160, lkaylor@augusta.edu ; Alicia Laszewski, Inflo Health, 954-683-7189, alicia@yourbrandethos.com

AUGUSTA, Ga. (June 13, 2023) – Augusta University Health (AU Health), a comprehensive primary, specialty, and subspeciality healthcare network based in Augusta, Georgia, that serves as the primary teaching affiliate for the Medical College of Georgia , announced today that they are partnering with Inflo Health , a radiology follow-up solution powered by advanced AI and natural language understanding (NLU). Augusta University Health will leverage Inflo Health’s innovative solution to automate the radiology follow-up process for hundreds of thousands of their radiology patients per year.

According to an American College of Radiology study, 60% of radiology imaging follow-ups never get completed. Inflo Health estimates that their platform allows their customers the ability to recapture at least 80% of these missed follow-ups.

“The radiology follow-up process can be challenging and time intensive, with life-changing consequences,” added John Crossgrove, Director of Radiology Services at AU Health. “Inflo Health is a smart and powerful technology that stood out to us during our search for a partner in this area for a multitude of reasons. The ability to automate and close the communication loop with 100% of our providers and patients in this area, across all modalities, without adding additional staff is transformational in supporting our world-class patient care mission and objectives.”

Inflo Health will support all areas within AU Health’s radiology program, including support to close any gaps within the incidental findings program. According to the ACR, incidental findings are defined as “an incidentally discovered mass or lesion, detected by CT, MRI, or other imaging modality performed for an unrelated reason.” Many different forms of cancers are discovered incidentally, and lifesaving therapies can be prescribed much earlier in the tumor development, leading to better patient outcomes.

Dr. Annette Johnson, AU Health’s Chair of Radiology and Imaging commented, “Complexity within health systems contributes to the reality that communication breakdowns are responsible for the majority of safety events in health care environments.  Test results management is a particularly substantial challenge for physicians and other providers, despite their diligence and focused efforts at information management.  Breakdowns in communication of test results occur across the spectrum of clinical settings and can result in delayed diagnoses and harm to patients. Our vision in AU Health Radiology is ‘Better imaging for better health.’ By partnering with Inflo Health, we can further this vision by creating automated processes for identification and tracking of imaging findings that require follow-up—so that we can have a failsafe system for providing timely and potentially life-saving testing and treatment to further ensure the delivery of the very best care for our patients. We are thrilled to have selected Inflo Health as our partner on this journey.”

Angela Adams, CEO of Inflo Health, said, “A recent article published by the American College of Radiology (ACR) cited that over 65% of Emergency Physicians and Radiologists report that their health systems do not have a tracking mechanism for incidental findings today. This is a staggering statistic given the importance of timely identification and communication for healthy patient outcomes. Augusta University Health is an innovative health system, and we are proud to partner with them on this mission-critical enhancement to their radiology team and their patients.” 

Inflo Health was founded by a revolutionary radiologist, frustrated by an overworked and inefficient healthcare system, who wanted to improve the patient outcomes. As a result, a team of clinical and technical experts came together to develop large language models and NLU to read and understand radiology reports with the goal of automating identification of which patients have recommendations for additional imaging. Inflo Health then automates communication to the care team and to the patients to help ensure the follow-ups are ordered and scheduled. The Inflo Health platform streamlines the management of radiology follow-up recommendations across all imaging modalities.

About Inflo Health: We harness the power of advanced AI, large language models, and NLU to turn radiology follow-up into a stress-free process. Our proven, automated solution streamlines the management of follow-up recommendations across all imaging modalities, so you can ensure no patient falls through the care gap. With our easy-to-use, integrated platform, your team can focus on delivering top-quality patient care, while also mitigating risk, and maximizing staff efficiency.

###

AU Health is Georgia’s only public academic health center, where world-class clinicians are bringing the medicine of tomorrow to patient care today. As the primary teaching affiliate of the Medical College of Georgia, AU Health provides the most comprehensive routine-to-complex care at AU Medical Center, which houses the region’s only Level 1 trauma center, as well as Children’s Hospital of Georgia, Georgia Cancer Center, historic Roosevelt Warm Springs Rehabilitation and Specialty Hospitals, Georgia War Veterans Nursing Home, and more than 100 primary and specialty care clinics across the state.

By Maria Thacker Goethe May 8, 2025
Disclaimer: This statement was published on May 9, 2025, at 12:11 PM and is subject to change as the administration moves forward with policy decisions. -- In a rapidly developing situation, the White House is poised to take executive action on prescription drug pricing that could significantly impact the biopharmaceutical industry. Early next week, the president is expected to sign an executive order directing administration officials to pursue a "Most Favored Nation" initiative, which would tie U.S. government drug payments to lower prices paid abroad, according to sources familiar with the matter who were granted anonymity to discuss internal deliberations. This executive order would bypass the legislative discussions previously reported in Congress, where Republicans on the House Energy and Commerce Committee had been considering similar measures as potential spending cuts. While the plan hasn't been finalized and could still change as officials work through specifics, the move signals the administration's intent to act quickly on drug pricing. If enacted, the MFN policy could be paired with other proposed changes, such as increasing the 23.1% Medicaid base rebate. Reports suggest that manufacturers might be required to pay either the MFN price or the higher rebate—whichever yields the lowest cost for the government. This policy would create severe financial pressure on drug developers, particularly small and mid-size companies that are essential to Georgia’s thriving life sciences ecosystem. Georgia is home to a growing network of biotech, pharmaceutical, and medical technology firms—many of which are advancing groundbreaking treatments for rare diseases, pediatric conditions, and underserved populations. These companies often operate with little commercial revenue and rely on a balanced, predictable pricing framework to continue investing in innovation. In 2023, pharmaceutical companies provided $54 billion in Medicaid rebates nationally, helping keep drug spending to just 5.9% of total Medicaid expenditures . The current system works by ensuring broad patient access to medicine while enabling companies to reinvest in research and development. Drastic changes such as MFN pricing would upend this balance and threaten job creation and investment in states like Georgia. Moreover, because Medicaid rebate amounts are tied to 340B discount calculations, the impact would extend far beyond Medicaid—further increasing costs in the already-burdened 340B program. In response, Georgia Life Sciences has joined a coalition of more than 40 state bioscience associations, signing onto a letter from the Council of State Bioscience Associations (CSBA) opposing any MFN or foreign reference pricing schemes. The letter highlights the harm such policies would inflict on rare disease patients, pediatric populations, and emerging biotechnology companies. “Rather than penalizing innovative companies that develop treatments for vulnerable patients, we should work together to ensure the U.S. maintains its strategic leadership in biopharmaceutical innovation and that American patients have access to the best treatments available.” — CSBA Letter, May 2025 Georgia Life Sciences is actively monitoring the situation and preparing to advocate on behalf of Georgia’s life sciences community.
By Sheran Brown May 1, 2025
Opinion: Georgia's Congressional delegation can lead the way on correcting 'pill penalty'  Maria Thacker Goethe President and CEO, Georgia Life Sciences: May 1, 2025 EPIC Act offers commonsense fix to 'pill penalty' problem
By Maria Thacker Goethe April 18, 2025
The Science & Community Impacts Mapping Project (SCIMaP) shows how proposed federal funding cuts lead to reduced economic activity and job losses nationwide.
MORE POSTS